

Galectin 3 (LGALS3), Medical 304

Table of Content

- [Purpose](#)
- [Description & Definitions](#)
- [Criteria](#)
- [Coding](#)
- [Document History](#)
- [References](#)
- [Special Notes](#)
- [Keywords](#)

| | |
|-------------------------|-------------|
| <u>Effective Date</u> | 12/2012 |
| <u>Next Review Date</u> | 6/2025 |
| <u>Coverage Policy</u> | Medical 304 |
| <u>Version</u> | 4 |

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details*.

Purpose:

This policy addresses the medical necessity of Galectin 3 (LGALS3).

Description & Definitions:

A lab analysis for Galectin 3 (LGALS3) a protein that is involved with cell growth, cell death, cell division cycle, cell adhesions and other cell functions. Mutations are associated with heart disease, stroke, cancer, fibrosis and inflammation.

Criteria:

Galectin 3 (LGALS3) is considered **not medically necessary** for any indication.

Coding:

Medically necessary with criteria:

| Coding | Description |
|--------|-------------|
| | None |

Considered Not Medically Necessary:

| Coding | Description |
|--------|-------------|
| 82777 | Galectin-3 |

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2024: June – criteria updated references updated
- 2020: January

- 2016: January, April

- 2015: January, February, October
- 2014: July, December
- 2013: January, February, March, July, August, September

Reviewed Dates:

- 2023: June
- 2022: June
- 2021: August
- 2020: August
- 2019: May
- 2018: May
- 2016: June, July

Effective Date:

- December 2012

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

Federal Register. Daily Journal of the United States Government. Retrieved 5.30.2024.
<https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=galectin+3>

U.S. Food and Drug Administration. Galectin-3 Reagent Kit . No date. Retrieved 5.30.2024.
https://www.accessdata.fda.gov/cdrh_docs/reviews/K140436.pdf

Hayes. A symplr company. Health Technology Assessment. Review :Aug 20, 2015. Galectin-3 In Vitro Diagnostic Assay (BG Medicine Inc.) For The Management Of Patients With Chronic Heart Failure. Retrieved 5.30.2024.
<https://evidence.hayesinc.com/report/htb.galectin2719>

MCG Informed Care Strategies. Retrieved 5.30.2024. <https://careweb.careguidelines.com/ed27/index.html>

Centers for Medicare and Medicaid Services. CMS.gov. Retrieved 5.30.2024.
<https://www.cms.gov/search/cms?keys=82777>

Commonwealth of Virginia. Department of Medical Assistance Services. Retrieved 5.30.2024.
<https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&qsc.q=82777&qsc.sort=>

Commonwealth of Virginia. Department of Medical Assistance Services. DMAS Fee Schedule. Retrieved 5.30.2024 <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

National Comprehensive Cancer Network. Retrieved 5.30.2024. <https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=galectin>

Carelon clinical guidelines and pathways. Retrieved 5.30.2024.
<https://guidelines.carelonmedicalbenefitsmanagement.com/no-search-results-found/>

Avalon. Biomarkers for Myocardial Infarction and Chronic Heart Failure. Policy Number: AHS – G2150. 1.2.2024. Retrieved 5.30.2024. <https://www.avalonhcs.com/wp-content/uploads/sentarahealth/G2150%20Biomarkers%20for%20Myocardial%20Infarction%20and%20Chronic%20Heart%20Failure.pdf>

BlueCross of Oklahoma. ST2 Assay for Chronic Heart Failure Policy Number: CPCPLAB040 Version 1.0 Plan Effective Date: Nov. 1, 2022. Retrieved 5.30.2024. <https://www.bcbsok.com/docs/provider/ok/standards/cpcp/avalon/cpcplab040-st2-assay-for-chronic-heart-failure-09-01-22.pdf>

Hara, A., Niwa, M., Noguchi, K., Kanayama, T., Niwa, A., Matsuo, M., Hatano, Y., & Tomita, H. (2020). Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. *Biomolecules*, 10(3), 389. Retrieved 5.30.2024. <https://doi.org/10.3390/biom10030389>

Sygitowicz, G., Maciejak-Jastrzębska, A., & Sitkiewicz, D. (2021). The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases. *Biomolecules*, 12(1), 46. Retrieved 5.30.2024. <https://doi.org/10.3390/biom12010046>

Special Notes: *

This medical policy expresses Sentara Health Plan's determination of medical necessity of services, and they are based upon a review of currently available clinical information. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Keywords:

SHP Galectin 3, LGALS3, SHP Medical 304, IgE-Binding Protein, MAC-2, Lectin L-29, L-34 CBP-30, Gal-3, Advanced Glycation End-Product Receptor 3, Lectin, Galactoside-Binding, Soluble, 3, Carbohydrate-Binding Protein 35, CBP 35, Galactose-Specific Lectin 3, Laminin-Binding Protein, 35 KDa Lectin, Galactoside-Binding Protein, GALBP, heart disease, stroke, cancer, fibrosis, inflammation, cell growth, cell death, cell division cycle, cell adhesions, L31; GAL3; MAC2; GALIG; LGALS2

